Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

NSAIDs modulate clonal evolution in Barrett's esophagus.

Kostadinov RL, Kuhner MK, Li X, Sanchez CA, Galipeau PC, Paulson TG, Sather CL, Srivastava A, Odze RD, Blount PL, Vaughan TL, Reid BJ, Maley CC.

PLoS Genet. 2013 Jun;9(6):e1003553. doi: 10.1371/journal.pgen.1003553.

2.

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus.

Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Sather CL, Kostadinov RL, Odze RD, Kuhner MK, Maley CC, Self SG, Vaughan TL, Blount PL, Reid BJ.

Cancer Prev Res (Phila). 2014 Jan;7(1):114-27. doi: 10.1158/1940-6207.CAPR-13-0289.

3.

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ.

PLoS Med. 2007 Feb;4(2):e67.

4.

Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ; Probar-study Group..

Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. doi: 10.1053/j.gastro.2011.08.036.

PMID:
21878200
5.

The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ.

Cancer Res. 2004 Oct 15;64(20):7629-33.

6.

Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.

Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, McGuigan J, Reynolds JV, Murray LJ.

Cancer Res. 2006 May 1;66(9):4975-82.

7.

Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.

Li X, Paulson TG, Galipeau PC, Sanchez CA, Liu K, Kuhner MK, Maley CC, Self SG, Vaughan TL, Reid BJ, Blount PL.

Cancer Prev Res (Phila). 2015 Sep;8(9):845-56. doi: 10.1158/1940-6207.CAPR-15-0130.

8.

Persistent clonal areas and clonal expansion in Barrett's esophagus.

Raskind WH, Norwood T, Levine DS, Haggitt RC, Rabinovitch PS, Reid BJ.

Cancer Res. 1992 May 15;52(10):2946-50.

9.

Surveillance in Barrett's esophagus: an audit of practice.

Ajumobi A, Bahjri K, Jackson C, Griffin R.

Dig Dis Sci. 2010 Jun;55(6):1615-21. doi: 10.1007/s10620-009-0917-y.

PMID:
19669878
10.

Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.

Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA.

Int J Cancer. 2005 Sep 10;116(4):584-91.

11.

MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.

Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E.

Cancer Prev Res (Phila). 2013 Mar;6(3):196-205. doi: 10.1158/1940-6207.CAPR-12-0276.

12.

Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.

Dolan K, Morris AI, Gosney JR, Field JK, Sutton R.

J Gastroenterol Hepatol. 2003 Jun;18(6):683-9.

PMID:
12753151
13.

Risk factors, DNA damage, and disease progression in Barrett's esophagus.

Olliver JR, Hardie LJ, Gong Y, Dexter S, Chalmers D, Harris KM, Wild CP.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5.

14.

Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.

Werther M, Saure C, Pahl R, Schorr F, R├╝schoff J, Alles JU, Heinm├Âller E.

Pathol Res Pract. 2008;204(5):285-94. doi: 10.1016/j.prp.2007.12.011.

PMID:
18337019
15.

Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.

Schneider JL, Zhao WK, Corley DA.

Dig Dis Sci. 2015 Feb;60(2):436-43. doi: 10.1007/s10620-014-3349-2.

16.

Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.

Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler HJ, Cleary KR, Troster M, Siewert JR, Roth JA.

J Thorac Cardiovasc Surg. 1996 Feb;111(2):323-31; discussion 331-3.

17.

Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.

Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE.

Am J Gastroenterol. 1997 Nov;92(11):2012-6.

PMID:
9362182
18.

[Demonstration of clonal heterogeneity in adenocarcinomas on Barrett's esophagus by flow cytometric study of cellular DNA content].

Robaszkiewicz M, Volant A, Hardy E, Nousbaum JB, Calament G, Cauvin JM, Bail JP, Lozach P, Gouerou H.

Gastroenterol Clin Biol. 1992;16(6-7):540-6. French.

PMID:
1526415
19.
20.

Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS.

Am J Gastroenterol. 2001 Oct;96(10):2839-48.

Items per page

Supplemental Content

Support Center